SI9720050B - Multivalent dtp-polio vaccines - Google Patents

Multivalent dtp-polio vaccines Download PDF

Info

Publication number
SI9720050B
SI9720050B SI9720050A SI9720050A SI9720050B SI 9720050 B SI9720050 B SI 9720050B SI 9720050 A SI9720050 A SI 9720050A SI 9720050 A SI9720050 A SI 9720050A SI 9720050 B SI9720050 B SI 9720050B
Authority
SI
Slovenia
Prior art keywords
immunogenic composition
composition according
toxoid
type
poliovirus
Prior art date
Application number
SI9720050A
Other languages
English (en)
Slovenian (sl)
Other versions
SI9720050A (sl
Inventor
Raafat E F Fahim
Larry U L Tan
Luis Barreto
John Thipphawong
Gail E D Jackson
Original Assignee
Connaught Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/672,530 external-priority patent/US6696065B1/en
Application filed by Connaught Lab filed Critical Connaught Lab
Publication of SI9720050A publication Critical patent/SI9720050A/sl
Publication of SI9720050B publication Critical patent/SI9720050B/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SI9720050A 1996-07-02 1997-07-02 Multivalent dtp-polio vaccines SI9720050B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/672,530 US6696065B1 (en) 1995-05-04 1996-07-02 Acellular pertussis vaccines and methods of preparation thereof
PCT/CA1997/000472 WO1998000167A1 (en) 1996-07-02 1997-07-02 Multivalent dtp-polio vaccines

Publications (2)

Publication Number Publication Date
SI9720050A SI9720050A (sl) 1999-12-31
SI9720050B true SI9720050B (en) 2001-12-31

Family

ID=24698948

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9720050A SI9720050B (en) 1996-07-02 1997-07-02 Multivalent dtp-polio vaccines

Country Status (20)

Country Link
EP (2) EP1762246A1 (pl)
JP (4) JP3280675B2 (pl)
CN (2) CN100408095C (pl)
AT (1) ATE339965T1 (pl)
AU (1) AU714493B2 (pl)
BR (2) BRPI9710460B8 (pl)
CA (1) CA2259415A1 (pl)
DE (1) DE69736709T2 (pl)
DK (1) DK0914153T3 (pl)
ES (1) ES2271969T3 (pl)
IL (1) IL127847A (pl)
NZ (1) NZ333989A (pl)
PL (1) PL187935B1 (pl)
PT (1) PT914153E (pl)
RO (1) RO120819B1 (pl)
RU (1) RU2194531C2 (pl)
SI (1) SI9720050B (pl)
SK (1) SK283565B6 (pl)
TR (1) TR199802783T2 (pl)
WO (1) WO1998000167A1 (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2303105A1 (en) * 1997-09-15 1999-03-25 Pasteur Merieux Msd Multivalent vaccines
EP1004314A1 (fr) * 1998-11-26 2000-05-31 Pasteur Merieux MSD Vaccin T.d. Polio rappel pour une population vaccinée ou sensibilisée
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
KR100401423B1 (ko) * 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법
EP2395073B1 (en) 2002-11-01 2017-09-06 GlaxoSmithKline Biologicals S.A. Drying process
RU2240819C2 (ru) * 2003-01-04 2004-11-27 Государственное учреждение Научно-исследовательский институт медицинских проблем Севера СО РАМН Способ вакцинопрофилактики коклюша, дифтерии и столбняка на крайнем севере
RU2228200C1 (ru) * 2003-01-20 2004-05-10 Красноярская государственная медицинская академия Способ профилактики акдс-вакциной на крайнем севере
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
EP1489092A1 (en) * 2003-06-18 2004-12-22 Institut Pasteur Modified Bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
GB0616306D0 (en) * 2006-08-16 2006-09-27 Novartis Ag Vaccines
GB0617602D0 (en) * 2006-09-07 2006-10-18 Glaxosmithkline Biolog Sa Vaccine
US8945582B2 (en) * 2006-09-07 2015-02-03 Glaxosmithkline Biologicals S.A. Vaccine
WO2008044611A1 (fr) 2006-09-29 2008-04-17 Japan Poliomyelitis Research Institute Vaccin de salk (ipv ) et contre la diphtérie, la coqueluche et le tétanos (dpt)
WO2009016651A1 (en) * 2007-07-31 2009-02-05 Panacea Biotec Limited Simplified means for obtaining prn from bordetella pertussis
EP2298344B1 (en) 2008-06-04 2016-08-17 The Chemo-Sero-Therapeutic Research Institute Use of inactivated japanese encephalitis virus particle as adjuvant
PE20100365A1 (es) 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
PE20100366A1 (es) 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
US20100330158A1 (en) * 2009-03-31 2010-12-30 Innopharma, Llc Protein-assisted drug delivery system for the targeted administration of active agents
EP3459562B1 (en) 2011-01-05 2024-03-20 Bharat Biotech International Limited A combination heptavalent vaccine
RS61723B1 (sr) * 2011-02-04 2021-05-31 Zoetis Services Llc Imunogenične bordetella bronchiseptica kompozicije
GB201106225D0 (en) * 2011-04-13 2011-05-25 Glaxosmithkline Biolog Sa Fermentation process
CN102861330B (zh) * 2012-06-29 2014-10-29 成都欧林生物科技股份有限公司 一种Hib多糖与精制破伤风类毒素偶联工艺
US20150273036A1 (en) * 2012-10-12 2015-10-01 Glaxosmithkline Biologicals Sa Non-cross-linked acellular pertussis antigens for use in combination vaccines
CN103007264A (zh) * 2012-12-14 2013-04-03 北京民海生物科技有限公司 b型流感嗜血杆菌结合疫苗及其应用
WO2014102265A1 (en) 2012-12-27 2014-07-03 Glycovaxyn Ag Methods and compositions relating to crm197
AP2015008702A0 (en) * 2013-03-08 2015-09-30 Crucell Holland Bv Acellular pertussis vaccine
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
AR101256A1 (es) 2014-07-21 2016-12-07 Sanofi Pasteur Composición vacunal que comprende ipv y ciclodextrinas
SI3204494T1 (sl) * 2014-10-07 2020-08-31 Serum Institute Of India Private Limited Izboljšane metode za neaktivacijo poliovirusa, adjuvans adsorpcije
RU2596919C2 (ru) * 2015-01-16 2016-09-10 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Комбинированная вакцина для профилактики коклюша, дифтерии, столбняка
RU2626532C2 (ru) * 2015-01-16 2017-07-28 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Комбинированная вакцина для профилактики коклюша, дифтерии, столбняка, гепатита в и инфекции, вызываемой haemophilus influenzae тип в
CN104707134A (zh) * 2015-03-27 2015-06-17 成都欧林生物科技股份有限公司 一种无细胞百日破联合疫苗及其制备方法
CN108570098B (zh) * 2017-12-29 2021-09-07 武汉生物制品研究所有限责任公司 一种百日咳多种抗原成分的分离纯化方法
WO2020165920A1 (en) * 2019-02-12 2020-08-20 Biological E Limited Multivalent vaccine composition
CN114302737A (zh) 2019-05-20 2022-04-08 索利吉尼克斯公司 制造三价线状病毒疫苗的组合物和方法
CN111000994A (zh) * 2019-12-26 2020-04-14 北京科兴中维生物技术有限公司 一种液体疫苗组合物及其制备方法与应用
CN111053898B (zh) * 2019-12-26 2023-05-16 北京科兴中维生物技术有限公司 一种疫苗组合物及其应用
WO2021176409A1 (en) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Preservative combination for vaccine composition

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3097140A (en) * 1958-10-31 1963-07-09 Merck & Co Inc Preparing a mixed polio, pertussis, tetanus, and diphtheria vaccine with benzethonium chloride
US4258029A (en) 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
US4705686A (en) 1986-05-09 1987-11-10 American Cyanamid Process for the preparation of acellular Bordetalla pertussis vaccine
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
GB8807860D0 (en) 1988-04-05 1988-05-05 Connaught Lab Pertussis vaccine
US5101014A (en) 1989-02-10 1992-03-31 United States Of America Process for the purification of a 69,000 da outer membrane protein of Bordetella pertussis
US5276142A (en) 1989-12-11 1994-01-04 American Cyanamid Company Process for purification of a 69000 dalton antigenic protein from Bordetella pertussis
GB9007657D0 (en) 1990-04-04 1990-05-30 Connaught Lab Purification of a pertussis outer membrane protein(omp69)
EP0484621A3 (en) * 1990-07-11 1992-08-26 American Cyanamid Company Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
IL101692A0 (en) * 1991-05-03 1992-12-30 Amgen Inc Recombinant b oligomer of pertussis toxin
FI945483A7 (fi) * 1992-05-23 1995-01-20 Smithkline Beecham Biologicals S A Hepatiitti B - pinta-antigeenejä ja muita antigeenejä sisältäviä yhdistelmärokotteita
DK0594950T3 (da) * 1992-10-27 1999-09-13 American Cyanamid Co Pædiatrisk kombinationsvaccine med forbedret immunogenicitet af hver vaccinekomponent
ATE221081T1 (de) * 1995-05-04 2002-08-15 Aventis Pasteur Azelluläre pertussis-impfstoffe und verfahren zu deren herstellung
TR199701547T1 (xx) * 1995-06-07 1998-03-21 Smithkline Beecham Biologicals S.A. Polisakarit antijen protein e�leni�i i�eren a��.
PL184872B1 (pl) * 1995-06-23 2003-01-31 Smithkline Beecham Biolog Kombinowana szczepionkaĆ zestaw do przygotowania kombinowanej szczepionkiĆ sposób wytwarzania kombinowanej szczepionki i jej zastosowanie

Also Published As

Publication number Publication date
CN1228709A (zh) 1999-09-15
IL127847A0 (en) 1999-10-28
BRPI9710460B1 (pt) 2019-02-05
PL331007A1 (en) 1999-06-21
NZ333989A (en) 2000-06-23
EP1762246A1 (en) 2007-03-14
PL187935B1 (pl) 2004-11-30
SK181898A3 (en) 2000-05-16
JP2006241171A (ja) 2006-09-14
ES2271969T3 (es) 2007-04-16
CN101310769B (zh) 2015-11-25
WO1998000167A1 (en) 1998-01-08
TR199802783T2 (xx) 1999-03-22
DK0914153T3 (da) 2007-01-29
ATE339965T1 (de) 2006-10-15
AU714493B2 (en) 2000-01-06
SK283565B6 (sk) 2003-09-11
CA2259415A1 (en) 1998-01-08
IL127847A (en) 2004-06-01
RU2194531C2 (ru) 2002-12-20
EP0914153A1 (en) 1999-05-12
JP2011121981A (ja) 2011-06-23
CN100408095C (zh) 2008-08-06
PT914153E (pt) 2007-01-31
EP0914153B1 (en) 2006-09-20
JP2002069002A (ja) 2002-03-08
AU3251697A (en) 1998-01-21
EP0914153B8 (en) 2006-11-02
DE69736709T2 (de) 2007-10-04
BR9710460A (pt) 1999-08-17
DE69736709D1 (de) 2006-11-02
BRPI9710460B8 (pt) 2021-05-25
JP2000504032A (ja) 2000-04-04
JP3280675B2 (ja) 2002-05-13
CN101310769A (zh) 2008-11-26
RO120819B1 (ro) 2006-08-30
SI9720050A (sl) 1999-12-31

Similar Documents

Publication Publication Date Title
SI9720050B (en) Multivalent dtp-polio vaccines
EP1296715B1 (en) Multivalent vaccine composition
EP1390066B1 (en) Vaccine composition
RU99101850A (ru) Поливалентные ассоциированные коклюшно-дифтерийно-столбнячно(акдс)-полиомиелитные вакцины
AU2001281895A1 (en) Vaccine Composition
JP2008120833A (ja) リン酸アルミニウム上に吸着したポリサッカライド結合抗原を含むワクチン組成物
AU2010201399B2 (en) Vaccine composition
HK1062891B (en) Vaccine composition
ZA200300755B (en) Multivalent vaccine composition.
HK1114779B (en) Multivalent vaccine composition
HK1114781B (en) Multivalent vaccine composition
HK1149900A (en) Vaccine composition
HK1055244B (en) Multivalent vaccine composition
HK1055244C (en) Multivalent vaccine composition

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20050412